PanOptica, Inc. was
Since then, guided by the deep and complementary experience of its founders, PanOptica has identified and evaluated more than 70 assets with the goal of licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic disease. In early 2011, PanOptica announced that it had raised $30 million in a Series A financing, led by two leading healthcare venture firms: SV Life Sciences and Third Rock Ventures.